For research use only. Not for therapeutic Use.
BBT is an enhancer of impaired glucose-stimulated insulin secretion (GSIS). BBT exhibits anti-hyperglycemia activity, and protects β-cells from cytokine- or streptozotocin (STZ)-induced cell death in type 2 diabetes models. BBT acts function via cAMP/PKA and long-lasting (L-type) voltage-dependent Ca2+ channel/CaMK2 pathway[1].
| Catalog Number | I040845 |
| CAS Number | 445000-45-3 |
| Synonyms | N-(2-benzoylphenyl)-5-bromothiophene-2-carboxamide |
| Molecular Formula | C18H12BrNO2S |
| Purity | ≥95% |
| InChI | InChI=1S/C18H12BrNO2S/c19-16-11-10-15(23-16)18(22)20-14-9-5-4-8-13(14)17(21)12-6-2-1-3-7-12/h1-11H,(H,20,22) |
| InChIKey | FCSCANHTNNHZOH-UHFFFAOYSA-N |
| SMILES | C1=CC=C(C=C1)C(=O)C2=CC=CC=C2NC(=O)C3=CC=C(S3)Br |
| Reference | [1]. Yao XG, et al. BBT improves glucose homeostasis by ameliorating 尾-cell dysfunction in type 2 diabetic mice. J Endocrinol. 2015 Mar;224(3):327-41. |
